Teva Pharmaceutical Industries, Ltd. and Active Biotech have amended their marketing and distribution agreement for oral laquinimod, an investigational drug for relapsing-remitting multiple sclerosis (RRMS). Under the new agreement, Teva extended its marketing and distribution rights to include the Nordic and Baltic regions and Active Biotech will receive higher royalties on sales in these territories. “We are very excited about the market potential of laquinimod. We believe that laqunimod c...